ArticleClinical genitourinary cancer2014

A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.

David S Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.